Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Tramadol | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Tramadol. |
| Trospium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Trospium. |
| Oxyphenonium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Oxyphenonium. |
| Benzatropine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Benzatropine. |
| Ziprasidone | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Ziprasidone. |
| Disopyramide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Disopyramide. |
| Amitriptyline | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Amitriptyline. |
| Ipratropium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Ipratropium. |
| Olanzapine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Olanzapine. |
| Metixene | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Metixene. |
| Terfenadine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Terfenadine. |
| Buclizine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Buclizine. |
| Clozapine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Clozapine. |
| Doxylamine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Doxylamine. |
| Trihexyphenidyl | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Trihexyphenidyl. |
| Oxyphencyclimine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Oxyphencyclimine. |
| Procyclidine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Procyclidine. |
| Profenamine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Profenamine. |
| Promazine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Promazine. |
| Hyoscyamine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Hyoscyamine. |
| Cyproheptadine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Cyproheptadine. |
| Imipramine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Imipramine. |
| Methscopolamine bromide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Methscopolamine bromide. |
| Chlorpromazine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Chlorpromazine. |
| Gallamine triethiodide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Gallamine triethiodide. |
| Darifenacin | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Darifenacin. |
| Tridihexethyl | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Tridihexethyl. |
| Triflupromazine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Triflupromazine. |
| Anisotropine methylbromide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Anisotropine methylbromide. |
| Nortriptyline | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Nortriptyline. |
| Amoxapine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Amoxapine. |
| Atropine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Atropine. |
| Nicardipine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Nicardipine. |
| Pirenzepine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Pirenzepine. |
| Paroxetine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Paroxetine. |
| Homatropine methylbromide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Homatropine methylbromide. |
| Rocuronium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Rocuronium. |
| Scopolamine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Scopolamine. |
| Benzquinamide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Benzquinamide. |
| Clidinium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Clidinium. |
| Propiomazine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Propiomazine. |
| Propantheline | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Propantheline. |
| Dicyclomine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Dicyclomine. |
| Biperiden | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Biperiden. |
| Brompheniramine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Brompheniramine. |
| Flupentixol | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Flupentixol. |
| Cocaine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Cocaine. |
| Quinidine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Quinidine. |
| Maprotiline | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Maprotiline. |
| Methantheline | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Methantheline. |
| Cycrimine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Cycrimine. |
| Glycopyrronium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Glycopyrronium. |
| Tolterodine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Tolterodine. |
| Oxybutynin | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Oxybutynin. |
| Promethazine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Promethazine. |
| Diphenhydramine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Diphenhydramine. |
| Doxacurium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Doxacurium. |
| Doxepin | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Doxepin. |
| Flavoxate | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Flavoxate. |
| Desipramine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Desipramine. |
| Orphenadrine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Orphenadrine. |
| Escitalopram | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Escitalopram. |
| Quetiapine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Quetiapine. |
| Mivacurium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Mivacurium. |
| Diphenidol | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Diphenidol. |
| Aripiprazole | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Aripiprazole. |
| Chlorprothixene | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Chlorprothixene. |
| Metocurine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Metocurine. |
| Pancuronium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Pancuronium. |
| Pipecuronium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Pipecuronium. |
| Methotrimeprazine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Methotrimeprazine. |
| Tiotropium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Tiotropium. |
| Solifenacin | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Solifenacin. |
| Isopropamide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Isopropamide. |
| Rapacuronium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Rapacuronium. |
| Mepenzolate | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Mepenzolate. |
| Pizotifen | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Pizotifen. |
| Fesoterodine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Fesoterodine. |
| Hexocyclium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Hexocyclium. |
| Dimetindene | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Dimetindene. |
| Aclidinium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Aclidinium. |
| Dexetimide | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Dexetimide. |
| Benactyzine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Benactyzine. |
| Umeclidinium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Umeclidinium. |
| Trimebutine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Trimebutine. |
| Dosulepin | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Dosulepin. |
| Imidafenacin | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Imidafenacin. |
| Butylscopolamine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Butylscopolamine. |
| Thonzylamine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Thonzylamine. |
| Methscopolamine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Methscopolamine. |
| Revefenacin | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Revefenacin. |
| Oxitropium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Oxitropium. |
| Propiverine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Propiverine. |
| Batefenterol | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Batefenterol. |
| Mebeverine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Mebeverine. |
| Tropatepine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Tropatepine. |
| Prifinium | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Prifinium. |
| Piperidolate | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Piperidolate. |
| Benzilone | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Benzilone. |
| Difemerine | The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Difemerine. |